Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How do tumor cells respond to HDAC inhibition?
Andrea Newbold, Katrina J. Falkenberg, H. Miles Prince, et al.
FEBS Journal (2016) Vol. 283, Iss. 22, pp. 4032-4046
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip J. Gotwals, Scott B. Cameron, Daniela Cipolletta, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 286-301
Closed Access | Times Cited: 867
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
David Tamborero, Carlota Rubio-Pérez, Ferran Muiños, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3717-3728
Open Access | Times Cited: 275
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
M. Janaki Ramaiah, Anjana Devi Tangutur, M. Rajasekhar Reddy
Life Sciences (2021) Vol. 277, pp. 119504-119504
Closed Access | Times Cited: 220
p53-Mediated Molecular Control of Autophagy in Tumor Cells
Maria Mrakovcic, Leopold F. Fröhlich
Biomolecules (2018) Vol. 8, Iss. 2, pp. 14-14
Open Access | Times Cited: 149
Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization
Marta Pérez-Hernández, Alain Arias, David Martínez‐García, et al.
Cancers (2019) Vol. 11, Iss. 10, pp. 1599-1599
Open Access | Times Cited: 137
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Roberta Mazzone, Clemens Zwergel, Antonello Mai, et al.
Clinical Epigenetics (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 133
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti–PD-L1 Therapy
Siyu Deng, Qianwen Hu, Heng Zhang, et al.
Molecular Cancer Therapeutics (2019) Vol. 18, Iss. 5, pp. 900-908
Open Access | Times Cited: 93
Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer
Hsiang‐Hsi Ling, Chih-Chia Kuo, Bo-Xing Lin, et al.
Experimental Cell Research (2016) Vol. 350, Iss. 1, pp. 218-225
Closed Access | Times Cited: 88
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Alexandre Perrier, Audrey Didelot, Pierre Laurent‐Puig, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1061-1061
Open Access | Times Cited: 73
Hypertranscription and replication stress in cancer
Akhil Bowry, Richard D. Kelly, Eva Petermann
Trends in cancer (2021) Vol. 7, Iss. 9, pp. 863-877
Open Access | Times Cited: 57
The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy
Brendan Moran, Maria Davern, John V. Reynolds, et al.
Cancer Letters (2023) Vol. 559, pp. 216121-216121
Open Access | Times Cited: 39
Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β -elemene scaffold
Yuan Gao, Ji‐Long Duan, Xia‐Wen Dang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 37
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer
Sravani Pulya, Ambati Himaja, Milan Paul, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12033-12058
Closed Access | Times Cited: 30
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Paulina Czajka‐Francuz, Maria J. Prendes, Arun K. Mankan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 24
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Роберто Пили, David I. Quinn, Hans J. Hammers, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 23, pp. 7199-7208
Open Access | Times Cited: 82
Calcium signalling and breast cancer
Choon Leng So, Jodi M. Saunus, Sarah J. Roberts‐Thomson, et al.
Seminars in Cell and Developmental Biology (2018) Vol. 94, pp. 74-83
Closed Access | Times Cited: 75
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
Maria Mrakovcic, Johannes Kleinheinz, Leopold F. Fröhlich
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 10, pp. 2415-2415
Open Access | Times Cited: 73
HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.
Wenqi Shan, Yuanyuan Jiang, Huimei Yu, et al.
PubMed (2017) Vol. 7, Iss. 5, pp. 1213-1226
Closed Access | Times Cited: 64
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
Epigenetic modulation in cancer immunotherapy
Stuart J. Gallagher, Elena Shklovskaya, Peter Hersey
Current Opinion in Pharmacology (2017) Vol. 35, pp. 48-56
Closed Access | Times Cited: 58
Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence
Luciana O. Almeida, Douglas Magno Guimarães, Manoela Domingues Martins, et al.
Stem Cell Research (2017) Vol. 21, pp. 94-105
Open Access | Times Cited: 56
HDAC inhibitors restore BRAF‐inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Stuart J. Gallagher, Dilini Gunatilake, Kimberley A. Beaumont, et al.
International Journal of Cancer (2017) Vol. 142, Iss. 9, pp. 1926-1937
Open Access | Times Cited: 52
A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation
Lena Hess, Verena Moos, Arnel A. Lauber, et al.
PLoS Genetics (2022) Vol. 18, Iss. 8, pp. e1010376-e1010376
Open Access | Times Cited: 26
Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
Yang Xu, Ping Li, Yang Liu, et al.
Cancer Communications (2022) Vol. 42, Iss. 6, pp. 493-516
Open Access | Times Cited: 24
Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy
Ruoyu Guo, Jixia Li, Jinxia Hu, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110417-110417
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top